Foundayo vs Tirzepatide: The Pill vs the Molecule
One is a brand-name daily pill. The other is a molecule sold as Zepbound, Mounjaro, or compounded tirzepatide. Here is the real-life difference - and one app that tracks both.
Quick answer
Foundayo and tirzepatide are not two brands of the same thing - one is a brand, the other is a molecule. Foundayo is Eli Lilly's brand name for orforglipron, a once-daily GLP-1 pill with no food or water rules, FDA-approved for weight management in April 2026. Tirzepatide is the active ingredient people meet as Zepbound (weight loss and sleep apnea), as Mounjaro (type 2 diabetes), or as compounded tirzepatide from a licensed pharmacy - a once-weekly shot working on two appetite signals, GLP-1 and GIP. Their trials were separate, not head-to-head: 12.4% average weight loss at Foundayo's highest dose among people who stayed on treatment in ATTAIN-1, 20.9% at tirzepatide's top dose in SURMOUNT-1, both over 72 weeks. MeAgain tracks either routine and keeps the history through any switch - 421K users, 4.8 stars across 21K App Store ratings.
Bottom line: This page is education, not medical advice. Medication choice and dose changes belong with your doctor or licensed clinician. MeAgain works with any GLP-1, branded or compounded, wherever it is prescribed.
Brand, Molecule, and Day-to-Day Differences
From the FDA labels - the differences you actually live with, not a which-is-better verdict. That call belongs to you and your doctor.
| Question | Foundayo | Tirzepatide |
|---|---|---|
| What it is | A brand name (Lilly) for orforglipron | A molecule - sold as Zepbound or Mounjaro, or compounded |
| How it's taken | Pill, once daily | Shot, once weekly |
| How it works | One hunger signal (GLP-1), non-peptide | Two hunger signals (GLP-1 + GIP), peptide |
| How long it lasts | About a day - hence daily | About 5 days - hence weekly |
| Food and water rules | None | None on timing; rotate injection sites |
| Approved for | Weight management (April 2026) | Weight management + sleep apnea (Zepbound); type 2 diabetes (Mounjaro) |
| Missed dose | Skip; resume next day - never double | Take within 4 days, else skip to the next week |
What MeAgain does not do: No medical advice, no diagnosis, no treatment, no insurance billing. MeAgain is a tracking and education app, not a clinical service — clinical decisions stay with your licensed clinician.
Key takeaways
Tirzepatide is a molecule, not a brand: the same active ingredient is sold as Zepbound for weight loss and sleep apnea, as Mounjaro for type 2 diabetes, and prepared as compounded tirzepatide by licensed pharmacies. Foundayo is a single brand: Lilly's daily orforglipron pill.
Foundayo is not a form of tirzepatide - a common mix-up worth clearing. It is a different molecule entirely (orforglipron), a non-peptide pill that works on the GLP-1 signal only, while tirzepatide is a peptide shot working on GLP-1 and GIP together.
The weekly rhythm differs at the chemistry level: Foundayo clears in about a day, so it is taken daily; tirzepatide lingers about 5 days, so it is injected weekly. MeAgain's medication graph draws whichever curve matches your prescription.
Their trials ran separately, never head-to-head, so the published weight-loss averages are a starting point for a conversation with your doctor rather than a scoreboard. The numbers and every caveat that comes with them are laid out plainly in the comparison further down this page.
Whichever side of this page you land on - the pill, a branded shot, or compounded tirzepatide - MeAgain tracks it: doses, sites, side effects on a 0-10 scale, food five ways, and a weight trend. 421K users, 4.8 stars across 21K ratings.
One Tracker for the Pill, the Pens, and the Vials
01A Medication Graph That Matches the Molecule
The clearest chemistry difference between these two shows up in MeAgain's medication graph. Foundayo clears in roughly a day, so the pill is daily and the graph draws a short daily curve - steady, as long as the habit holds. Tirzepatide hangs around for about 5 days, so the shot is weekly and the graph draws a rise, a peak, and a slow fade toward the next dose. That fade is why day two on tirzepatide can feel different from day six, and why a daily pill asks for a different kind of consistency than a weekly ritual. Appetite, water intake, and side effects often track that curve more closely than people expect, which is why seeing it drawn out changes how the week reads. Set your medication and dose, and the graph tells the week's story either way.
02Dose Steps Without the Guesswork
Both medications climb a ladder, and both ladders reward a clean log. Foundayo steps from 0.8 mg up toward 17.2 mg, each step at least 30 days. Tirzepatide steps from 2.5 mg - a starter month, not a treatment dose - up toward 15 mg, each step at least 4 weeks. The week after a step-up is usually the one that decides how people feel about their medication, and it is also the week most worth logging carefully. MeAgain keeps the current step, the date you started it, and the symptoms that followed on one screen, which is exactly the record you want in hand when the next step is on the table. The app never decides the dose - it makes the conversation with your doctor better informed.
03Shot Details, Sites, and Rotation - for Every Tirzepatide Form
If your tirzepatide comes as a Zepbound pen, a Mounjaro pen, or a compounded vial from a licensed pharmacy, the weekly mechanics are the same: log the dose, log the site, rotate next time. MeAgain records the injection site on a body map - abdomen, thigh, upper arm - and rotates you to a different spot automatically for the next shot, which the label recommends to keep skin healthy. Compounded users get the same tracking as pen users: the app tracks by molecule and routine, not by packaging.
04One Timeline, However the Prescription Reads
GLP-1 journeys rarely stay on one product: people move between brands, between the pill and a shot, sometimes between a pen and a compounded preparation, as coverage and availability shift. MeAgain is built so that none of those moves costs you your history. Weight trend, food logs, side-effect entries, and dose dates stay on a single timeline while the medication setup changes on top. Six months from now, the question will not be what an average trial participant did - it will be what your body did, and the answer will be in your own chart.
Foundayo vs Tirzepatide, Sorted Out Plainly
Clearing Up the Names
Searches for this comparison usually mean one of two things, and both deserve a straight answer. If you are asking whether Foundayo is a new form of tirzepatide: no. Foundayo is orforglipron, a chemically different, non-peptide molecule that works on the GLP-1 receptor only. If you are asking how Lilly's new pill compares with the tirzepatide you know - a Zepbound or Mounjaro pen, or a compounded vial - that is the comparison this page makes.
The tirzepatide side covers more ground than one brand. Zepbound is the weight-management and sleep-apnea brand; Mounjaro is the same molecule approved for type 2 diabetes; and licensed pharmacies prepare compounded tirzepatide prescribed by clinicians. Foundayo, by contrast, is one product: a daily tablet approved for weight management in April 2026, with no diabetes approval as of July 2026.
The Numbers, With Their Caveats
Foundayo's pivotal obesity trial, ATTAIN-1, followed 3,127 adults for 72 weeks; the highest dose - among people who stayed on treatment - averaged 12.4% body-weight loss, with 59.6% of those participants losing at least 10%. Tirzepatide's SURMOUNT-1 followed 2,539 adults for 72 weeks; the top dose averaged 20.9%. The two trials enrolled different people at different times - they cannot be read as a race result.
Side-effect profiles overlap heavily - nausea, constipation, diarrhea, vomiting, stomach discomfort, fatigue - because both quiet appetite through the same signal family. The differences sit at the edges: Foundayo's label lists burping and hair loss among its common effects; injectable tirzepatide adds injection-site reactions. Both carry the same serious class warning on thyroid C-cell tumors seen in rodents. Individual tolerance varies enough that your own 0-10 log will tell you more than any trial table.
Pill, pen, or vial: MeAgain tracks by molecule and routine, not by packaging - and it works with any GLP-1, branded or compounded, wherever it is prescribed. If the prescription changes later, the history stays.
This content is for informational purposes only and does not constitute medical advice. Medication choice, dose changes, and side-effect management belong with your doctor or licensed clinician. Foundayo, Zepbound, and Mounjaro are Eli Lilly medications.
Sources
- Foundayo (orforglipron) Prescribing Information (Eli Lilly)
- Zepbound (tirzepatide) Prescribing Information (Eli Lilly)
- Jastreboff AM et al. - Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1, NEJM 2022, n=2,539)
- FDA Novel Drug Approvals 2026 (Foundayo, April 1, 2026)
- GoodRx - Orforglipron vs Tirzepatide (brand/molecule primer)
What Users Tracking Either One Say
Built for the Molecule Era, Not One Brand
The comparison that actually matters happens in a log, not a spec sheet. One App Store reviewer three weeks into a GLP-1 (Berdr004, June 27, 2026) put it this way:
it has helped me see the connection between feeling pretty bad after a shot and actually feeling pretty good. I am only 3 weeks in and I'm starting to get into a rhythm.
That connection - dose on one line, how the days felt on the next - is what MeAgain is for, whether the dose is a daily pill or a weekly shot.
GLP-1 prescriptions now come as brand pens, daily pills, and compounded preparations - and people move between them. MeAgain tracks the routine you actually have: dose reminders, site rotation for shots, side effects on a 0-10 scale, food five ways, and one weight trend through every change.
What Our Users Say
“I've been using the app for about 7 months now and I love how I'm able to track my meals and my daily medication. The little capybara widget is a great visual to help me know what my body needs.”
“This app does exactly what I needed with tracking shots… location, time, amount, current medication level, and reminders for the next one. That plus weight progress is all I needed, and after trying at least 5 others this was the only one that did it in a clean, logical way- and didn't cost a fortune!”
“I really love this app and how easy it is to use for my food, water, Mounjaro weekly shot and everything else. The app is totally worth the cost and it's been perfect for me.”
“I've been on my MJ journey since September 2025. Seeing my food intake has made a huge difference. Also, reviewing my shot locations has helped me remember to rotate. I have recommended this app to my friends who have also started their own journeys!”
“I love tracking water, protein and fiber on the app. It's really cool it's able to pull my weight and steps too. Add the widget to you phone screen if you do get it, I love that.”
Foundayo vs Tirzepatide - FAQs
No - this is the most common mix-up in this comparison. Foundayo is Eli Lilly's brand name for orforglipron, a chemically distinct, non-peptide pill that works on the GLP-1 signal only. Tirzepatide is a different molecule - a peptide that works on GLP-1 and GIP together - sold as Zepbound and Mounjaro and also prepared as compounded tirzepatide. Same company on the branded side, same drug family, different molecules.
Your Journey Back to You,
One Day at a Time
Track the plan, dose, meals, and milestones in one place that actually keeps up with your day.